Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Behav Neurol ; 2022: 9401661, 2022.
Article in English | MEDLINE | ID: mdl-36419591

ABSTRACT

Objective: Although the prognosis of posterior reversible encephalopathy syndrome (PRES) is usually favourable and most patients wholly recover, the disorder can result in death in some patients. To date, the data on clinical features and risk factors for death are still lacking; therefore, we aim to investigate the clinical features and long-term prognostic risk factors of PRES in the present study. Methods: The patients with PRES were identified from the First Affiliated Hospital of Zhengzhou University from June 2011 to June 2020. Clinical characteristics, laboratory tests, magnetic resonance imaging examinations, and treatment of all patients were analyzed retrospectively. All patients were followed up by telephone. Finally, the patients were divided into the survival group and death group for prognosis analysis. Results: A total of 92 patients with PRES were included; 84.8% of whom were female, with an average age of 25.4 (5-66) years at the onset of PRES. Epilepsy was the main clinical manifestation (72.8%). The in-hospital mortality rate was 2.17%. The 3-year all-cause survival rate for PRES patients was 86%. In univariate analysis, patients with systemic lupus erythematosus (P = 0.027) and blood transfusion history within 1 month before onset (P = 0.027), need for dialysis (P ≤ 0.001), nephritis (P = 0.010), stroke (P = 0.016), and heart failure (P = 0.016) were associated with death. In multivariate analysis, we found that heart failure (OR = 0.095, 95% CI 0.020 to 0.441) and stroke (OR = 0.033, 95% CI 0.002 to 0.467) were independent risk factors for death in PRES patients, while pregnancy was a protective factor for death in PRES patients (OR = 7.978, 95% CI 1.446 to 44.006). Conclusions: Our results indicate that PRES could be considered as a sign of a very high-risk patient. We also demonstrated that heart failure and stroke were independent risk factors for death in patients with PRES; moreover, pregnancy was a protective factor.


Subject(s)
Heart Failure , Posterior Leukoencephalopathy Syndrome , Stroke , Humans , Female , Adult , Male , Posterior Leukoencephalopathy Syndrome/diagnostic imaging , Posterior Leukoencephalopathy Syndrome/complications , Retrospective Studies , Risk Factors , Stroke/complications
2.
Neurol Sci ; 35(8): 1229-33, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24584634

ABSTRACT

This study aimed to investigate the effects of catalpol on ATPase and amino acids in gerbils following cerebral ischemia/reperfusion (CI/R) injury. Gerbil model of CI/R was prepared by bilateral common carotid occlusion for 10 min followed by 6 h of reperfusion. Catalpol (5, 10 or 20 mg/kg per day) was injected intraperitoneally for 3 days before the carotid occlusion. Stroke index was measured during the reperfusion. ATPase activity, glutamate (Glu) and aspartate contents in brain tissue homogenate were examined. The results showed that catalpol significantly improved the stroke index compared with sham group (P < 0.05 or P < 0.01). Catalpol markedly increased the activities of Na(+)-K(+)-ATPase and Ca(2+)-ATPase (P < 0.05 or P < 0.01), and significantly decreased the content of Glu in brain tissue (P < 0.05 or P < 0.01). These data suggest that the efficacy of catalpol pretreatment on CI/R injury is associated with the enhancement of ATPase activity and the inhibition of excitatory amino acid toxicity.


Subject(s)
Adenosine Triphosphatases/analysis , Aspartic Acid/analysis , Brain Chemistry/drug effects , Brain Ischemia/drug therapy , Glutamic Acid/analysis , Iridoid Glucosides/therapeutic use , Nerve Tissue Proteins/analysis , Neuroprotective Agents/therapeutic use , Reperfusion Injury/drug therapy , Animals , Brain Ischemia/metabolism , Carotid Artery, Common , Cell Membrane/enzymology , Constriction , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Female , Gerbillinae , Iridoid Glucosides/administration & dosage , Iridoid Glucosides/chemistry , Iridoid Glucosides/pharmacology , Male , Models, Animal , Molecular Structure , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacology , Premedication , Reperfusion Injury/metabolism , Single-Blind Method
SELECTION OF CITATIONS
SEARCH DETAIL
...